Download PDF
Thromb Haemost 1999; 82(05): 1510-1515
DOI: 10.1055/s-0037-1614863
Rapid Communications
Schattauer GmbH

Immunological Quantitation of Rabbit Plasminogen Activator Inhibitor-1 in Biological Samples

Evidence that Rabbit Platelets Do not Contain PAI-1
Thu-Hoa Ngo
1   From the Laboratory for Pharmaceutical Biology and Phytopharmacology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Belgium
,
Paul J. Declerck
1   From the Laboratory for Pharmaceutical Biology and Phytopharmacology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 06 April 1999

Accepted after revision 02 June 1999

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

Two immunoassays for the specific quantitation of rabbit plasminogen activator inhibitor-1 (PAI-1) antigen and activity in biological samples were developed and applied for the evaluation of PAI-1 in rabbits. Levels of PAI-1 antigen in rabbit plasma were 9.8 ± 4.6 ng/ml (mean ± SD, n = 6), with a corresponding value of 20.5 ± 13.5 ng/ml for PAI-1 activity. In rabbit serum PAI-1 antigen was 11.8 ± 4.9 ng/ml (n = 6) and PAI-1 activity was 2.9 ± 2.0 ng/ml (n = 6). Endotoxin injection (20 μg/kg, iv) induced a time-dependent increase of both PAI-1 antigen and PAI-1 activity levels in rabbit plasma, eventually resulting in a 40- to 90-fold increase (p <0.0001 vs baseline). A linear correlation was found between PAI-1 antigen and activity levels in normal plasma (r = 0.90, n = 6, p <0.05) and in plasma from endotoxin-treated rabbits (r = 0.98, n = 20, p <0.001). Analysis of PAI-1 antigen and activity in lysates of washed rabbit platelets revealed the absence of PAI-1 (i.e. <0.03 ng/108 platelets).

In conclusion, development of specific immunological assays allowed the quantitation of PAI-1 in rabbit samples. In striking contrast to other species (human, rat, mouse, pig) rabbit platelets lack detectable amounts of PAI-1 (i.e. >100-1000 fold lower vs other species studied). This observation may have important implications for the use of experimental rabbit models especially in studies on the role of platelets in various pathological conditions including thrombosis and atherosclerosis.

Key words

Thrombosis - fibrinolysis - serpin - atherosclerosis - platelets
 

  • References

  • 1 Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13.
    PubMedGoogle Scholar
  • 2 Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis. J Int Med 1994; 236: 425-32.
    CrossrefPubMedGoogle Scholar
  • 3 Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 263-76.
    PubMedGoogle Scholar
  • 4 Diéval J, Nguyen G, Gross S, Delobel J, Kruithof EKO. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type-1. Blood 1991; 77: 528-32.
    PubMedGoogle Scholar
  • 5 Lee MH, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81: 2357-62.
    PubMedGoogle Scholar
  • 6 Schleef RR, Higgins DL, Pillemer E, Levitt L.J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1747-52.
    CrossrefPubMedGoogle Scholar
  • 7 Fay WP., Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Complete deficiency of plasminogen activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-33.
    CrossrefPubMedGoogle Scholar
  • 8 Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
    PubMedGoogle Scholar
  • 9 Declerck PJ, Verstreken M, Collen D. An immunofunctional assay for active plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 1988; 2: 77-8.
    PubMedGoogle Scholar
  • 10 Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1305-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Ngo TH, Verheyen S, Knockaert I, Declerck PJ. Monoclonal antibody-based immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples. Thromb Haemost 1998; 79: 808-12.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Collen D, Stassen JM, Verstraete M. Thrombolysis with human entrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 1983; 71: 368-76.
    CrossrefPubMedGoogle Scholar
  • 13 Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JM, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-8.
    CrossrefPubMedGoogle Scholar
  • 14 Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of plateletrich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-25.
    CrossrefPubMedGoogle Scholar
  • 15 Hofmann KJ, Mayer EJ, Schultz LD, Socher SH, Reilly CF. Purification and characterisation of recombinant rabbit plasminogen activator inhibitor-1 expressed in Saccharomyces cerevisiae. Fibrinolysis 1992; 6: 263-72.
    PubMedGoogle Scholar
  • 16 Ngo TH, Bijnens AP, Knockaert I, Declerck PJ. Expression, purification and characterization of recombinant rat plasminogen activator inhibitor-1. Fibrinolysis 1997; 11: 37-43.
    PubMedGoogle Scholar
  • 17 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-53.
    PubMedGoogle Scholar
  • 19 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-33.
    CrossrefPubMedGoogle Scholar
  • 20 Wiman B, Lindahl T. Almquist $ Evidence for a discrete binding protein of plasminogen activator inhibitor in plasma. Thromb Haemost 1988; 59: 392-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Muller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-61.
    PubMedGoogle Scholar
  • 22 Bijnens AP, Knockaert I, Cousin E, Kruithof EKO, Declerck PJ. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1. Thromb Haemost 1997; 77: 350-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Colucci M., Paramo JA, Collen D. Generation in plasma a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-24.
    CrossrefPubMedGoogle Scholar
  • 24 Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
    CrossrefPubMedGoogle Scholar
  • 25 Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-Neutralizing monoclonal antibody. Circulation 1995; 91: 1175-81.
    CrossrefPubMedGoogle Scholar
  • 26 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-7.
    PubMedGoogle Scholar
  • 27 Lang IM, Marsh JJ, Konopka RG, Olman MA, Binder BR, Moser KM, Schleef RR. Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation 1993; 87: 1990-2000.
    CrossrefPubMedGoogle Scholar
  • 28 Konkle BA, Schick PK, He X, Liu RJ, Mazur EM. Plasminogen activator inhibitor -1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler Thromb 1993; 13 (05) 669-74.
    CrossrefPubMedGoogle Scholar
  • 29 Alessi MC, Chomiki N, Berthier R, Schweitzer A, Fossat C, Juhan-Vague I. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization. Thomb Haemost 1994; 72 (06) 931-6.
    PubMedGoogle Scholar